← All trials
NCT05342272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2017
- Primary completion
- Jan 26, 2018
- Completion date
- Oct 30, 2018
- First posted
- Apr 22, 2022
- Last posted
- Apr 22, 2022
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spedali Civili di BresciaLead sponsor
- Spedali Civili di BresciaReponsible party - principal investigator
- University of BresciaOverall official - principal investigator
- Spedali Civili di BresciaSponsor investigator
- University of BresciaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.